Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BLACK DIAMOND THERAPEUTICS, INC.

(BDTX)
  Rapport
Vertraagde tijd Nasdaq  -  19:00 25-11-2022
2.180 USD   +7.92%
15/11Black Diamond Therapeutics vraagt $500 miljoen aan bij de Mixed Shelf
MT
08/11Black Diamond Therapeutics, Inc. Rapporteert winstresultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2022
CI
08/11Black Diamond Therapeutics, Inc. Benoemt Melanie Morrison tot Senior Vice President, Development Operations
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
ETF's gepositioneerd op BLACK DIAMOND THERAPEUTICS, INC.ETF's en trackers met Trackinsight
ETF gewichtVariatie 5 dagenRatingGeografie
IShares Nasdaq US Biotechnology (D) - USD0.01%-0.21%VS
IShares Nasdaq US Biotechnology - USD0.01%-0.18%VS
IShares Micro-Cap ETF - USD0.01%0.71%VS
Invesco Nasdaq Biotechnology ETF - USD0.01%0.38%-VS
Fidelity NASDAQ Composite Index ETF - USD0%0.94%-VS



Copyright © 2009 Morningstar. All Rights Reserved. The information, data and opinions expressed (ďInformationĒ) and contained herein: (1) are proprietary to Morningstar and/or its content providers and are not intended to represent investment advice or recommendation to buy or sell any security; (2) may not be copied or distributed without express license to do so; and (3) are not warranted to be accurate, complete or timely. Morningstar reserve its rights to charge for access to these Ratings and/or Rating report. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this Rating, Rating Report or Information contained therein.
Grafiek BLACK DIAMOND THERAPEUTICS, INC.
Duur : Periode :
Black Diamond Therapeutics, Inc. : Grafische technische analyse Black Diamond Therapeutics, Inc. | MarketScreener
Grafiek op volledig scherm
Evolutie van de resultatenrekening
Consensus
Verkoop
Koop
Gemiddeld advies Accumuleren
Aantal analisten 6
Laatste slotkoers 2,18 $
Gemiddelde koersdoel 6,75 $
Spread / Gemiddelde doel 210%
Grafiek BLACK DIAMOND THERAPEUTICS, INC.
Duur : Periode :
Black Diamond Therapeutics, Inc. : Grafische technische analyse Black Diamond Therapeutics, Inc. | MarketScreener
Grafiek op volledig scherm
Sector en concurrentie
Verschil t.o.v. 1 jan (%)Kapitalisatie (M$)
BLACK DIAMOND THERAPEUTICS, INC.-59.10%79
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930